JMT202 / CSPC Pharma - LARVOL DELTA

JMT202-002: a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: Shanghai JMT-Bio Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia • Hypertriglyceridemia

a Phase Ib/Ⅱa Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetic Characteristics of JMT202 Injection in Participants With Hypertriglyceridemia (clinicaltrials.gov) - P1/2 | N=48 | Not yet recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P1/2 trial • Dyslipidemia • Hypertriglyceridemia

JMT202 (RECOMBINANT FULLY HUMAN ANTI-βKLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (HKEXnews) - "The board of directors (the 'Board') of CSPC Pharmaceutical Group Limited (the 'Company', together with its subsidiaries, the 'Group') is pleased to announce that JMT202 (the 'Product'), a recombinant fully human anti-βKlotho monoclonal antibody drug developed by the Group, has beenn approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S....The indication for this clinical trial approval is hypertriglyceridemia (HTG)."

IND • Hypertriglyceridemia

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202 (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Shanghai JMT-Bio Inc.

New P1 trial